Immunome, Inc. IMNM · Stock Open Immunome, Inc. in new tab
Immunome, Inc. Analysis (IMNM)
Is Immunome, Inc. a good investment? Immunome, Inc. (IMNM) is currently trading at 23.01 USD. Market analysts have a consensus price target of 35.77 USD. This suggests a potential upside from current levels.
Earnings Schedule: Immunome, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.12.
Investor FAQ
Does Immunome, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Immunome, Inc.?
Immunome, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -2.39.
Company Profile
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Community Discussion